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Amylin, a 37 amino acid C-terminal amidated peptide is an integral part of secretory granules of pancreaticp-cells. Utilizing a specific radioimmuno- 
assay system we demonstrate in the present study a cosecretion of amylin and insulin from the isolated rat pancreas. The secretion pattern of both 
peptides during glucose or glucose plus arginine stimulation is identical. The molar ratio of amylin amounts to 10% of that of insulin. The biological 
significance of amylin is still unknown, but a paracrine/endocrine role in glucose homeostasis speculated. 
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1. INTRODUCTION 2.3. Perfusion experiments 
Amylin, a 37 amino acid peptide processed from a 89 
(human, [l]) or 93 (rat, [2]) amino acid precursor, was 
originally isolated from the pancreatic amyloid obtain- 
ed from type II diabetics [3,4] and from human in- 
sulinoma [5]. Recent studies demonstrated amylin, also 
termed islet amyloid polypeptide (IAPP, [3]) and 
diabetes-associated peptide (DAB, 4), as a normal 
product of pancreatic fl, but not of A-, D- or PP-cells 
colocalized with insulin into secretory granulae [5,6]. 
These findings and the demonstrated inhibition of 
insulin-stimulated glycogen synthesis in skeletal muscle 
[7,8] suggested a possible role for amylin in the 
pathogenesis of type II diabetes [9,10]. The present 
study was performed to establish the pattern of amylin 
secretion in combination with insulin and amylin from 
rat pancreas. This was possible since a radioim- 
munoassay system is now available. 
Rats were anesthetized by an i.p. injection of sodium pentobar- 
bitone (45 mg/kg b.w.). The pancreas, spleen, stomach, and prox- 
imal part of the duodenum were perfused through cannulated 
abdominal aorta and coeliac axis as described before [1 1] and detail- 
ed previously [12]. The entire preparation was removed from the 
cadaver and placed into a perfusion chamber (37°C). The perfusion 
media consisted of a Krebs-Henseleit bicarbonate buffer (pH 7.4 
when gassed with 95% 0~ and 5% COz). The venous effluent was col- 
lected in intervals of 1 and 5 min, respectively, by a cannula inserted 
into the portal vein. The flow rate was constant at 4 ml/min. One per- 
fusion experiment lasted 40 min. After a basal period of 10 min for 
equilibration (2.8 mmol/l glucose) the buffer was changed to medium 
supplemented with 10 mmol/l glucose or 10 mmol/l glucose plus 10 
mmol/l arginine. 
2.4. Analytical determinations 
2. MATERIALS AND METHODS 
2.1. Reagents 
Insulin in perfusate was measured by radioimmunoassay [13]. The 
standard was a mixture of rat insulin I and II and was obtained from 
Novo (Mainz, FRG). Amylin in perfusate was determined by 
radioimmunoassay kit for rat amylin (Peninsula, Merseyside, UK) 
using a rabbit antiserum specific for rat amylin. The antiserum cross- 
reacts with rat amylin lOO%, human amylin 13%, rat CGRP 
< O.Ol%, rat CGRP II < 0.01% and porcine NPY 0%. Standard was 
synthetic rat amylin (1-128 pg/ml). Integrated insulin and amylin 
secretion was determined as secretion rate of the first (O-10 min) and 
the second phase (1 l-20 min) of the biphasic insulin response from 
the isolated perfused rat pancreas. 
Bovine serum albumin (fraction V) was from Serva (Heidelberg, 
FRG) and aprotinin (Trasylol) from Bayer (Leverkusen, FRG). All 
other chemicals were of analytical grade and were purchased from 
Merck (Darmstadt, FRG). 
Data are given as mean + S.E.M. of n=6 experiments in each 
group. 
3. RESULTS 
2.2. Animals 
Male albino Wistar rats (180-240 g) kept in a light- and 
temperature controlled room were fed a standard diet (Altromin, 
Lage, FRG) and had free access to water. 
After perfusion of isolated pancreata by media con- 
taining 10 mmol/l glucose or 10 mm0111 glucose plus 10 
mmol/l arginine a typical biphasic insulin secretion pat- 
tern was observed (figs 1 and 2). Arginine potentiated 
the insulinotropic action of glucose (fig.2). 
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Amylin was also released in a biphasic manner. The 
pattern of amylin release was identical with insulin (figs 
1 and 2). The molar amount of amylin secreted was 
about 10% of that of insulin during glucose (phase 1: 
2975 + 322 fmol insulin, 434+ 126 fmol amylin 
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Fig. 1, Secretion of insulin and amylin-like immunoreactivity from 
the isolated perfused rat pancreas under basal conditions (O-10 min) 
and during stimulation with 10 mmol/l glucose (1 l-40 min). IRI, 
insulin-like immunoreactivity; ALI, amylin-like immunoreactivity. 
(14.5@!0); phase 2: 17235 rt2718 fmol insulin, 2135 f 392 
fmol amylin (12.4~0) and glucose plus arginine stimula- 
tion (phase 1: 13975 t808 fmol insulin, 1417+218 
fmol/l amylin (10.1%); phase 2: 92270 22484 fmol in- 
sulin, 8804& 1678 fmol amylin (9.5010)). There was no 
change of the secreted insulin/amylin ratio during both 
phases of stimulated hormone release, 
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Fig.2. Secretion of insulin and amylin-like immunoreactivity from 
the isolated perfused rat pancreas under basal conditions (O-10 min) 
and during stimulation with 10 mmol/l glucose plus 10 mmol/l 
arginine (11-40 min). IRI, insulin-like immunorea~ivity; ALI, 
amyiin-like ~mmunor~ctivity. 
4. DISCUSSION 
Recent studies demonstrated amylin, the major com- 
ponent of pancreatic amyloid found in type II diabetes, 
as a normal product of pancreatic p-cells [5,6]. There 
is evidence that amylin represents a biological active 
peptide: the carboxy-terminal end of amylin is 
amidated [14] and it inhibits the insulin-stimulated 
glycogen synthesis of skeietal muscle [7,8]. Recently, 
we observed an inhibition of somatostatin secretion 
from isolated rat pancreas (Fehmann, M.C., un- 
published observation). Therefore, endocrine and 
paracrine functions of amylin can be speculated in 
regulation of glucose homeostasis. 
Using polymerase chain reactions Ferrier et al. found 
in islets an amylin hybridisation signal intensity of ap- 
proximately 10% of that of insulin 1151. The present 
study now shows for the first time that amylin is releas- 
ed from the isolated rat pancreas revealing an identical 
secretion pattern like insulin (figs 1 and 2). The molar 
amount of secreted amylin was about 10% of that of 
insulin. This suggests amylin as a hormone produced by 
pancreatic p-cells and coreleased with insulin into cir- 
culation. The physiological role of amylin is still 
unknown. 
In conclusion our data suggest amylin as a new 
secretory product of rat pancreatic &cells which is cor- 
eleased with insulin. 
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